Shares of Intelligent Bio Solutions Inc. (INBS) more than doubled today after the medical technology company announced a strategic manufacturing partnership with Syrma Johari MedTech Ltd for its flagship Intelligent Fingerprinting Drug Screening Reader.
The partnership is intended to support and scale the production of the Intelligent Fingerprinting Drug Screening Reader and also support long-term margin improvement.
The Intelligent Fingerprinting Drug Screening System is designed to detect recent use of substances commonly encountered in the workplace, such as opioids, cocaine, methamphetamine, and cannabis, by analyzing sweat from fingerprints. This non-invasive, portable system serves as a deterrent against drug abuse and encourages employees to adhere to health and safety policies.
In December 2024, the company submitted its 510(k) premarket notification to the FDA for review and clearance of its Intelligent Fingerprinting Drug Screening System. The FDA has requested additional information, and the company is in the process of evaluating the FDA's questions and working toward resubmitting a new 510(k) notification. However, outside the U.S., it is commercially available in many countries, including Chile, the United Kingdom, Australia, and Scandinavia, to name a few.
The partnership with Syrma Johari is expected to result in annual production cost savings of more than 40%, translating to an expected improvement of roughly 20 percentage points in gross margin compared with its previous manufacturing arrangement. Additionally, Syrma Johari's manufacturing capacity is approximately four times Intelligent Bio's current capacity, positioning the company to efficiently support anticipated demand as it scales commercial operations. The collaboration is also expected to strengthen Intelligent Bio's global manufacturing strategy, reduce reliance on a single supplier and build greater resilience into its supply chain.
The company is targeting a 2026 U.S. market entry for the Intelligent Fingerprinting Drug Screening Reader, subject to regulatory clearance.
A 1-for-10 reverse split of Intelligent Bio's common stock came into effect on December 16, 2025. As of this writing, INBS is at $8.97, up 119%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.